Maravai Lifesciences Holdings Stock Performance
| MRVI Stock | USD 5.29 0.07 1.34% |
The company secures a Beta (Market Risk) of 1.07, which conveys a somewhat significant risk relative to the market. Maravai Lifesciences returns are very sensitive to returns on the market. As the market goes up or down, Maravai Lifesciences is expected to follow. At this point, Maravai Lifesciences has a negative expected return of -0.65%. Please make sure to verify Maravai Lifesciences' treynor ratio, kurtosis, as well as the relationship between the Kurtosis and day typical price , to decide if Maravai Lifesciences performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Maravai Lifesciences Holdings has generated negative risk-adjusted returns adding no value to investors with long positions. Despite abnormal performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in December 2024. The recent confusion may also be a sign of long-lasting up-swing for the firm traders. ...more
Actual Historical Performance (%)
One Day Return 1.92 | Five Day Return 12.24 | Year To Date Return (21.07) | Ten Year Return (82.18) | All Time Return (82.18) |
1 | Acquisition by Gray Susannah of 24000 shares of Maravai Lifesciences subject to Rule 16b-3 | 09/06/2024 |
2 | Acquisition by Kevin Herde of 1861 shares of Maravai Lifesciences at 5.83 subject to Rule 16b-3 | 09/27/2024 |
3 | Acquisition by Andrew Burch of 1841 shares of Maravai Lifesciences at 5.7 subject to Rule 16b-3 | 10/31/2024 |
4 | Disposition of 8409946 shares by Gtcr Investment Xi Llc of Maravai Lifesciences subject to Rule 16b-3 | 11/06/2024 |
5 | Maravai LifeSciences stock plunges on weak Q3 results, lowered guidance | 11/07/2024 |
6 | Maravai LifeSciences Holdings Inc Q3 2024 Earnings Call Highlights Navigating ... | 11/08/2024 |
7 | Robert W. Baird Cuts Maravai LifeSciences Price Target to 9.00 | 11/11/2024 |
8 | Maravai lifesci director John DeFord acquires 100,625 in stock | 11/14/2024 |
9 | Disposition of 4363 shares by Rebecca Buzzeo of Maravai Lifesciences at 4.42 subject to Rule 16b-3 | 11/15/2024 |
| Begin Period Cash Flow | 632.1 M |
Maravai |
Maravai Lifesciences Relative Risk vs. Return Landscape
If you would invest 916.00 in Maravai Lifesciences Holdings on August 28, 2024 and sell it today you would lose (387.00) from holding Maravai Lifesciences Holdings or give up 42.25% of portfolio value over 90 days. Maravai Lifesciences Holdings is currently does not generate positive expected returns and assumes 6.1326% risk (volatility on return distribution) over the 90 days horizon. In different words, 54% of stocks are less volatile than Maravai, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Maravai Lifesciences Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Maravai Lifesciences' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Maravai Lifesciences Holdings, and traders can use it to determine the average amount a Maravai Lifesciences' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1063
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | MRVI |
Estimated Market Risk
| 6.13 actual daily | 54 54% of assets are less volatile |
Expected Return
| -0.65 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.11 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Maravai Lifesciences is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Maravai Lifesciences by adding Maravai Lifesciences to a well-diversified portfolio.
Maravai Lifesciences Fundamentals Growth
Maravai Stock prices reflect investors' perceptions of the future prospects and financial health of Maravai Lifesciences, and Maravai Lifesciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Maravai Stock performance.
| Return On Equity | -0.43 | ||||
| Return On Asset | -0.0161 | ||||
| Profit Margin | (0.81) % | ||||
| Operating Margin | (0.23) % | ||||
| Current Valuation | 723.34 M | ||||
| Shares Outstanding | 141.84 M | ||||
| Price To Earning | 7.79 X | ||||
| Price To Book | 2.15 X | ||||
| Price To Sales | 4.76 X | ||||
| Revenue | 288.94 M | ||||
| Gross Profit | 714.04 M | ||||
| EBITDA | 712.41 M | ||||
| Net Income | (119.03 M) | ||||
| Cash And Equivalents | 617.45 M | ||||
| Cash Per Share | 4.69 X | ||||
| Total Debt | 610.97 M | ||||
| Debt To Equity | 0.69 % | ||||
| Current Ratio | 7.22 X | ||||
| Book Value Per Share | 2.44 X | ||||
| Cash Flow From Operations | 126.22 M | ||||
| Earnings Per Share | (1.67) X | ||||
| Market Capitalization | 1.32 B | ||||
| Total Asset | 1.49 B | ||||
| Retained Earnings | 285.74 M | ||||
| Working Capital | 612.44 M | ||||
About Maravai Lifesciences Performance
By evaluating Maravai Lifesciences' fundamental ratios, stakeholders can gain valuable insights into Maravai Lifesciences' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Maravai Lifesciences has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Maravai Lifesciences has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 126.12 | 89.24 | |
| Return On Tangible Assets | (0.13) | (0.12) | |
| Return On Capital Employed | (0.02) | (0.02) | |
| Return On Assets | (0.08) | (0.08) | |
| Return On Equity | (0.29) | (0.27) |
Things to note about Maravai Lifesciences performance evaluation
Checking the ongoing alerts about Maravai Lifesciences for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Maravai Lifesciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Maravai Lifesciences generated a negative expected return over the last 90 days | |
| Maravai Lifesciences has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 288.94 M. Net Loss for the year was (119.03 M) with profit before overhead, payroll, taxes, and interest of 714.04 M. | |
| Maravai Lifesciences has a strong financial position based on the latest SEC filings | |
| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from gurufocus.com: Disposition of 4363 shares by Rebecca Buzzeo of Maravai Lifesciences at 4.42 subject to Rule 16b-3 |
- Analyzing Maravai Lifesciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Maravai Lifesciences' stock is overvalued or undervalued compared to its peers.
- Examining Maravai Lifesciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Maravai Lifesciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Maravai Lifesciences' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Maravai Lifesciences' stock. These opinions can provide insight into Maravai Lifesciences' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Maravai Stock analysis
When running Maravai Lifesciences' price analysis, check to measure Maravai Lifesciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Maravai Lifesciences is operating at the current time. Most of Maravai Lifesciences' value examination focuses on studying past and present price action to predict the probability of Maravai Lifesciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Maravai Lifesciences' price. Additionally, you may evaluate how the addition of Maravai Lifesciences to your portfolios can decrease your overall portfolio volatility.
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Money Managers Screen money managers from public funds and ETFs managed around the world |